DIA Biosimilars 2013

Royalty Pharma

Royalty Pharma’s offer lapses, withdraws judicial review

Wednesday, June 19, 2013 01:38 PM

Royalty Pharma has withdrawn its request for a judicial review of the Irish Takeover Panel's decision that required it to lapse its offer for Elan once shareholders approved its Share Repurchase Program at a special shareholders’ meeting Monday. Shareholders approved a $200 million share buyback.

More... »

Cenduit: Now with Patient Reminders

Elan shareholders approve one of four transactions

Monday, June 17, 2013 03:30 PM

Elan shareholders approved one of four transactions up for a vote at its special meeting Monday. Shareholders rejected plans for a $1 billion cash acquisition of a 21% stake in Theravance’s royalties from the respiratory franchise it shares with GSK; acquisition of Vienna, Austria-based AOP Pharmaceuticals for $348.8 million; and the spinout of ELND005 into a new Irish startup Speranza Therapeutics, with $70 million in funding.

More... »

CRF Health – eCOA Forum

Elan to proceed with formal sale process

Friday, June 14, 2013 02:38 PM

Elan has announced it is proceeding with a formal sale process in light of the expressions of interest received to date. As part of this process, Royalty Pharma will be invited to participate. Elan has urged shareholders not to tender into the current Royalty Pharma offer.

More... »

Royalty Pharma makes firm offer to acquire Elan

Tuesday, April 16, 2013 09:41 AM

Echo Pharma Acquisition (Royalty Pharma) announced the terms of a firm, all cash offer for the entire issued and to be issued share capital of Elan. 

More... »

Astellas to sell diabetes patents

Friday, July 1, 2011 10:13 AM

Japanese drug maker Astellas Pharma is selling its diabetes-related patents to a fund for $609 million, to then be invested in strategic initiatives, according to Reuters.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2013 CenterWatch.